治疗卵巢癌新药rucaparib临床疗效良好
发布时间：2019-05-17 02:57
【摘要】：正克洛维斯肿瘤科学公司宣布更新PARP1和PARP2强抑制剂rucaparib治疗有BRCA基因突变的晚期卵巢癌Ⅱ期临床试验资料,证实具有令人非常信服的临床疗效。Ⅱ期临床ARIEL2试验研究了rucaparib对204名卵巢癌患者的疗效。有BRCA基因突变患者的平均无病情加重存活时间为9.4个月,生物标记物阴性者为3.7个月,临床效果十分显著。有BRCA基因突变患者82%(32/39)达到实体瘤治疗效果评价标准RECIST和肿瘤标记物CA-125测定的有效标准,只达到RECIST有效反应者为69%(27/39),疾病控制率为73%;生物标记物阴性患者疗效较差,只有21%(13/62)达到实体瘤治疗效果评价标准RECIST和肿瘤标记
[Abstract]:N Clovis Oncology Science announced the updating of phase II clinical trial data for the treatment of advanced ovarian cancer with BRCA gene mutation with PARP1 and PARP2 strong inhibitor rucaparib. Phase II clinical ARIEL2 trial studied the efficacy of rucaparib in 204 patients with ovarian cancer. The average survival time was 9.4 months in patients with BRCA gene mutation and 3.7 months in patients with negative biomarker. The clinical effect was very significant. 82% (32 鈮，
本文编号：2478749
[Abstract]:N Clovis Oncology Science announced the updating of phase II clinical trial data for the treatment of advanced ovarian cancer with BRCA gene mutation with PARP1 and PARP2 strong inhibitor rucaparib. Phase II clinical ARIEL2 trial studied the efficacy of rucaparib in 204 patients with ovarian cancer. The average survival time was 9.4 months in patients with BRCA gene mutation and 3.7 months in patients with negative biomarker. The clinical effect was very significant. 82% (32 鈮，
本文编号：2478749
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2478749.html
最近更新
教材专著
